Topics:

Alzheimer's investigators pick Lilly's sola in big prevention study

Tools

Eli Lilly's ($LLY) solanezumab has secured an endorsement from Alzheimer's researchers, who will study the experimental drug as a preventive therapy against the memory-robbing disease in patients before symptoms emerge.

Lilly last year revealed that it would revive its own efforts to develop the amyloid drug, which failed in a pair of Phase III studies last year despite showing signs of efficacy in patients with mild disease. Now the drug has a new lease on life with the help of the so-called A4 study, which has won funding from the NIH's National Institute on Aging.   

The going theory is that drugs that clear amyloid--a hallmark of Alzheimer's--don't work once the disease advances. In the new study, investigators want to give sola another shot. The study aims to focus on slowing memory decline by 30%, targeting patients between ages 70 and 85 with early markers for the disease but no symptoms, Reuters reported. Led by Dr. Reisa Sperling from Brigham & Women's Hospital in Boston, the 1,000-patient study is expected to take years and yield final results in 2018.

New treatments can't come fast enough for the more than 5 million Americans suffering from Alzheimer's disease, which health officials and policymakers have flagged as a costly threat to the aging U.S. population. Offering very little help, Big Pharma's gambles on amyloid-blocking drugs have ended in big losses, including Pfizer ($PFE) and Johnson & Johnson's ($JNJ) failed Phase III trials for "bapi" last year. But Roche's ($RHHBY) Genentech, Lilly and others are banking on drugs to succeed as preventive therapies.

We'll see how these players fare with their bold bets, but apparently not for 5 years or so as far as the A4 study is concerned.

- here is BWH's release
- see the Reuters article

Related Articles:
Eli Lilly ditches FDA filing for Alzheimer's hope solanezumab
Alzheimer's investigators see fresh sign of solanezumab success in Eli Lilly study
Eli Lilly surges on conflicting data for Alzheimer's drug solanezumab
Is there an Alzheimer's Act II in the cards for bapi, solanezumab?